Filtered By:
Condition: Atrial Fibrillation
Nutrition: Vitamins
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2092 results found since Jan 2013.
Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III
CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.PMID:37732457 | DOI:10.1161/CIRCULATIONAHA.122.060315
Source: Circulation - September 21, 2023 Category: Cardiology Authors: Stuart J Connolly Jeff S Healey Emilie P Belley-Cote Kumar Balasubramanian Domenico Paparella Katheryn Brady Wilko Reents Bernhard C Danner P J Devereaux Mukul Sharma Chinthanie Ramasundarahettige Salim Yusuf Richard P Whitlock Source Type: research
Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia
Conclusion: Being men, a previous event and DOAC-switch posed a higher risk for all study outcomes. direct oral anticoagulants had a protective effect against cerebral bleeding in comparison to vitamin K antagonists. Adherence to direct oral anticoagulants resulted in lower risk of stroke and cerebral bleeding. We found no differences in the risk of stroke and gastrointestinal bleeding when we compared direct oral anticoagulants vs. vitamin K antagonists.
Source: Frontiers in Pharmacology - September 15, 2023 Category: Drugs & Pharmacology Source Type: research
Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study
ConclusionPoor adherence to NOACs is associated with increased risks of thromboembolism and all-cause mortality. The minimal adherence threshold should be ≥ 90%, preferably even ≥ 95%.
Source: Cardiovascular Drugs and Therapy - September 14, 2023 Category: Cardiology Source Type: research
Direct oral anticoagulants versus vitamin K antagonists: Which one is more effective in atrial fibrillation
CONCLUSIONS: Our meta-analysis demonstrates that in patients undergoing bioprosthetic valve surgery and presenting with AF afterward, DOAC and VKA are similar regarding life-threatening and all-cause mortality outcomes, including major bleeding, stroke, and intracranial hemorrhage.PMID:37697799 | DOI:10.1177/02676591231202383
Source: Perfusion - September 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Alireza Khodadadiyan Kimia Jazi Hamed Bazrafshan Drissi Helia Bazroodi Mina Mashayekh Erfan Sadeghi Ghazal Gholamabbas Mehdi Bazrafshan Mahdi Rahmanian Source Type: research
Short-term antithrombotic strategies after left atrial appendage occlusion: a systematic review and network meta-analysis
Conclusion: No significant difference was found among patients receiving DAPT, DOACs, and VKA in terms of stroke, DRT, and major bleeding events after LAAO. The SUCRA indicated that DAPT was ranked the worst among all antithrombotic strategies due to the higher risk of stroke, DRT, and major bleeding events, while VKAs were ranked the preferred antithrombotic strategy. However, DOACs are worthy of consideration due to their advantage of convenience.
Source: Frontiers in Pharmacology - September 1, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis
CONCLUSIONS: Among AF patients with ESRD on chronic hemodialysis, the risk of ischemic stroke, ischemic stroke or systemic embolism, minor bleeding, major bleeding, and all-cause mortality is similar in patients treated with DOACs compared to VKAs. Given that the meta-analysis of RCTs on gastrointestinal bleeding did not confirm the results of the meta-analysis of the observational studies, it cannot be concluded that gastrointestinal bleeding is lower among DOAC-treated patients.PROTOCOL REGISTRATION: PROSPERO CRD42023391966.PMID:37648582 | DOI:10.1016/j.ejim.2023.08.020
Source: European Journal of Internal Medicine - August 30, 2023 Category: Internal Medicine Authors: Ioannis Kyriakoulis Anastasia Adamou Iliana Stamatiou David Dimitris Chlorogiannis Ioannis Kardoutsos Despoina Koukousaki George Ntaios Source Type: research
Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis
ConclusionDOACs are associated with more favorable safety outcomes and may be a feasible option of oral anticoagulant for individuals with atrial fibrillation and cirrhosis. Pending validation by randomized prospective studies, the findings of this study should be interpreted with caution.
Source: American Journal of Cardiovascular Drugs - August 28, 2023 Category: Cardiology Source Type: research
Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry
CONCLUSION: This Win Ratio analysis demonstrates the significant benefits of NOACs over warfarin and ABC pathway adherence over nonadherence in reducing the composite outcome in patients with AF.PMID:37625457 | DOI:10.1055/s-0043-1772773
Source: Thrombosis and Haemostasis - August 25, 2023 Category: Hematology Authors: Sukrit Treewaree Gregory Y H Lip Rungroj Krittayaphong Source Type: research
Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial
EuroIntervention. 2023 Aug 22:EIJ-D-23-00206. doi: 10.4244/EIJ-D-23-00206. Online ahead of print.ABSTRACTAbout one-third of patients undergoing transcatheter aortic valve implantation (TAVI) use oral anticoagulants (OAC), mainly due to atrial fibrillation. General guidelines advise interrupting OAC in patients with a high risk of bleeding undergoing interventions. However, preliminary observational data suggest that the continuation of OAC during TAVI is safe and may reduce the risk of periprocedural thromboembolic events. The Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter ...
Source: EuroIntervention - August 22, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Dirk-Jan van Ginkel Willem L Bor Christophe L F Dubois Hugo M Aarts Maxim J P Rooijakkers Kees H van Bergeijk Liesbeth Rosseel Leo Veenstra Ole De Backer Nicolas M Van Mieghem Frank van der Kley Adriaan Wilgenhof Remigio Leonora Jonathan Halim Carl E Scho Source Type: research
Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4 –5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
AbstractThe role of direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) and stage 4 –5 chronic kidney disease (CKD) is controversial. Electronic medical records from 2012 to 2021 were retrieved for patients with AF and stage 4–5 CKD receiving oral anticoagulants. Patients were separated into those receiving DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) or vitamin K ant agonists (VKA). Primary outcomes included ischemic stroke (IS), systemic thrombosis (SE), major bleeding, gastrointestinal bleeding, hemorrhagic stroke, acute myocardial infarction, cardiovascular death, and all-cause dea...
Source: Journal of Thrombosis and Thrombolysis - August 21, 2023 Category: Hematology Source Type: research
